Corneal Ulcer Market to Increase at a Steady Growth Rate During the Study Period (2020-2034) | DelveInsight [Yahoo! Finance]
Kiora Pharmaceuticals, Inc. (KPRX)
Company Research
Source: Yahoo! Finance
attributed to the anticipated launch of emerging therapies and the increasing cases of corneal ulcer. LAS VEGAS June 25, 2024 /PRNewswire/ -- DelveInsight's Corneal Ulcer Market Insights report includes a comprehensive understanding of current treatment practices, corneal ulcer emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany France Italy , and Spain ) and the United Kingdom , and Japan ]. Key Takeaways from the Corneal Ulcer Market Report According to DelveInsight's analysis, the market size for corneal ulcers is expected to grow significantly by 2034. CL-related infectious keratitis has been shown to exhibit a female predominance of 57–69% , whereas trauma-related infectious keratitis is associated with a male predominance of 74–78% Leading corneal ulcer companies such as Dompé Farmaceutici S.p.A, Claris Biotherapeutics, Inc. ReGenTree, LLC , and others
Show less
Read more
Impact Snapshot
Event Time:
KPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPRX alerts
High impacting Kiora Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KPRX
News
- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies [Yahoo! Finance]Yahoo! Finance
- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) had its price target raised by analysts at HC Wainwright from $2.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation [Yahoo! Finance]Yahoo! Finance
- Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors [Yahoo! Finance]Yahoo! Finance
KPRX
Earnings
- 8/9/24 - Beat
KPRX
Analyst Actions
- 8/22/24 - HC Wainwright
KPRX
Sec Filings
- 9/12/24 - Form 4
- 9/11/24 - Form 4
- 8/20/24 - Form 4
- KPRX's page on the SEC website